



# Comparative Proteomic Analysis of *Escherichia coli* Under Ofloxacin Stress

## Ofloksasin Stresi Altında *Escherichia coli*'nin Karşılaştırmalı Proteomik Analizi

Engin KOÇAK<sup>1\*</sup>, Ceren ÖZKUL<sup>2</sup>

<sup>1</sup>Hacettepe University Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey

<sup>2</sup>Hacettepe University Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Ankara, Turkey

### ABSTRACT

**Objectives:** In the present study, proteomics was utilized to evaluate changes in *Escherichia coli* proteins in response to ofloxacin to understand the mechanism of action of ofloxacin and the mechanisms of ofloxacin resistance in *E. coli*.

**Materials and Methods:** Proteomics analysis of *E. coli* was performed by using liquid chromatography quadrupole time-of-flight mass spectrometry followed by a data processing step using MaxQuant. Functional classification and pathway analysis showed a systematic effect of ofloxacin over *E. coli* proteome structure.

**Results:** In total, 649 common proteins were identified in the untreated and ofloxacin-treated groups, while 98 proteins were significantly different in the ofloxacin-treated group. Functional classification and pathway analysis showed that ofloxacin has a systematic effect over ribosomal processes, energy pathways (tricarboxylic acid cycle and glycolysis), membrane proteins, microbial targets, and biofilm formation.

**Conclusion:** The results showed that ofloxacin affected many cellular processes and pathways. In addition, proteomic analysis revealed that *E. coli* develops resistance mechanism with different biological processes.

**Key words:** Proteomics, LC/MS, antibiotic resistance, ofloxacin, *E. coli*

### ÖZ

**Amaç:** Bu çalışmada ofloksasinin etki mekanizmasına karşı yanıt olarak *Escherichia coli* proteinlerinde görülen değişikliklerin belirlenmesi ve *E. coli*'deki oflotoksin direnç mekanizmalarının değerlendirilmesi için proteomiks kullanılmıştır.

**Gereç ve Yöntemler:** *E. coli*'nin proteomik analizi sıvı kromatografisi/kuadrupol uçuş zamanlı kütle spektroskopisi kullanarak gerçekleştirilmiş ve sonrasında veri proselme aşaması MaxQuant kullanarak yapılmıştır. İşlevsel sınıflandırma ve yolak analizi oflotoksinin *E. coli*'nin proteome yapısına sistematik bir etkisinin olduğunu göstermiştir.

**Bulgular:** Çalışmada 649 tane sıklıkla rastlanan proteinin yapısı oflotoksin ile muamele edilen ve edilmeyen gruplarda belirlenirken, 98 proteinin oflotoksin ile muamele gören grupta belirgin derecede farklı olduğunu göstermiştir. İşlevsel sınıflandırma ve yolak analizi oflotoksinin ribosomal prosesler, enerji yolları (trikarboksilik asit siklusu ve glikoliz), membran proteinleri, mikrobiyal hedefler ve biofilm oluşumu üzerine sistematik bir etkisinin olduğunu göstermiştir.

**Sonuç:** Bu sonuçlar ofloksasinin birçok hücresel prosesi ve yolağı etkilediğini göstermiştir. Ayrıca, proteomik analizler *E. coli*'nin farklı biyolojik prosesler ile direnç mekanizması geliştirdiğini göstermiştir.

**Anahtar kelimeler:** Proteomik, LC/MS, antibiyotik direnci, ofloksasin, *E. coli*

\*Correspondence: kocakengin@hotmail.com, Phone: +90 546 720 23 52, ORCID-ID: orcid.org/0000-0002-1076-1300

Received: 05.12.2019, Accepted: 21.02.2020

©Turk J Pharm Sci, Published by Galenos Publishing House.

## INTRODUCTION

Antibiotic resistance is one of the most pressing health issues worldwide. Improper use of antibiotics has led to the emergence of resistant microorganisms.<sup>1,2</sup> A more detailed understanding of antibiotic-bacteria interactions is key to increasing the efficiency of antibiotic use as well as developing novel combination treatment strategies. In recent years, omics-based technologies have emerged in bacterial antibiotic resistance.<sup>3,4</sup> Mass spectrometry (MS)-based proteomics is a powerful method for the comprehensive characterization of proteome structure and to understand the cellular process at the protein level within an organism. In microbiology, proteomics is a promising approach to understanding the effect of antibiotics on bacteria and resistance mechanisms against antibiotics.<sup>5-7</sup>

Ofloxacin is one of the second-generation fluorinated quinolones with broad-spectrum antibacterial activity against most Gram-negative and, Gram-positive bacteria, including anaerobes.<sup>8,9</sup> Ofloxacin inhibits the activity of DNA gyrase and topoisomerase IV in DNA replication. Alterations in the target enzymes (DNA gyrase and topoisomerase IV) by chromosomal mutations is the main mechanism of resistance.<sup>9</sup> However, the contribution of proteins to resistance still requires explanation for a deeper understanding of bacteria-fluoroquinolone interactions.

The present study aimed to evaluate the effects of ofloxacin on *Escherichia coli* at the protein level. Apart from its broad-spectrum activity on clinically important infections, ofloxacin is also renowned for its wide application in livestock production and its high frequency in environmental sources such as surface water.<sup>10,11</sup> Livestock and environmental sources are emerging due to its high capacity for horizontal gene transfer of antimicrobial resistance genes. Thus, the present study is also important for elucidating the potential resistance mechanisms of bacteria against ofloxacin.

## MATERIALS AND METHODS

### *Bacterial culture and minimum inhibitory concentration (MIC) experiments*

*E. coli* ATCC 25922 was cultured on tryptic soy agar (TSA). In order to confirm the MIC value of ofloxacin against *E. coli*, standard broth microdilution was performed according to the method reported by the Clinical Laboratory Standards Institute.<sup>12</sup> The MIC value of ofloxacin was determined and compared with the latest breakpoint tables of European Committee on Antimicrobial Susceptibility Testing (EUCAST).<sup>13</sup> For proteomics experiments, the 0.5x MIC value for ofloxacin was used (0.01 mg/L). *E. coli* ATCC 25922 was cultured on Mueller Hinton Broth (MHB) and incubated at 37°C until the log phase was achieved. The bacterial suspension was prepared using MHB containing 0.01 mg/L ofloxacin to obtain a bacterial concentration of  $5 \times 10^5$  cfu/mL bacteria. For the control group, the same concentration of the bacterial culture was also prepared without adding any antibiotics. Flasks were incubated at 37°C for 20 h for proteomics experiments. A bacterial growth curve was constructed for 48 hours by plotting time against the log 10 cfu/mL values. Colony counting for each hour was

performed by serial dilution and inoculation of the bacterial suspension into TSA.

### *Sample preparation for proteomics*

After the incubation period, the cultures were centrifuged, and washed with phosphate buffered saline in triplicate. The bacterial cells were disrupted using lysis buffer containing lysozyme. Protein concentrations of ofloxacin in the treated and control groups were calculated by using the Bio-Rad DC assay. The chloroform (Sigma)/methanol (Sigma)/water co-solvent system was used for protein extraction.

Extracted proteins were suspended in 100 mM ammonium bicarbonate solution (Sigma). As a reducing agent, 200 mM dithiothreitol (DTT) (Sigma) was used. Proteins were incubated with DTT at 56°C for 20 min. After reduction, proteins were incubated with 100 mM iodoacetamide (Sigma) at room temperature. Proteins were digested with trypsin (1:100 (w/w)) at 37°C for 16 hours. After desalting, tryptic peptides were dissolved in acetonitrile that contained 0.1% formic acid.

### *Liquid chromatography/quadrupole time-of-flight/MS (LC/QTOF) analysis*

Peptides were analyzed in a LC/QTOF/MS platform. They were separated in C18 columns [Zorbax C18 column 150x0.05 mm, 5 column 1 Å (Agilent)] at 55°C performed with an Agilent 1290 high performance LC. A total volume of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) was used as the mobile phase, and the flow rate was adjusted to 0.070 mL/min. Peptides were eluted with a gradient of 1%-55% mobile phase B over 80 minutes, followed by 55%-85% mobile phase B over 5 minutes. The total gradient run time was 90 minutes. Post run was 25 minutes.

Peptides were analyzed in an Agilent 6530 QTOF/MS system in positive-ion mode of the electrospray ionization source. The capillary voltage was adjusted at 4000 V with a drying temperature of 350°C. Automated MS/MS data of peptides were recorded between 300 m/z and 1400 m/z above the 1500-count threshold.

The six most intense ions were selected for MS/MS analysis. The ion charge states were +2, +3, and +4. The fragmentation energy was adjusted to 45 V. Twenty micrograms of protein was loaded onto the LC/MS system for each run. Four technical replicates were analyzed for each of ofloxacin-treated and control groups.

### *Protein identification and quantification*

The recorded MS/MS data were processed using Maxquant (Max Planck Institute, Germany, <https://www.maxquant.org>). The *E. coli* database was downloaded from UniprotKB. Peptides and proteins were identified by matching the recorded MS/MS data with *in silico* MS/MS data. In the matching process, 20 ppm mass tolerance was used for the first and main search. Carboamidomethylation on cysteine and oxidation on methionine were chosen as fixed and variable modifications, respectively. Two missed cleavages were allowed. In the identification process, the false discovery rate (FDR) value was selected as 0.01 for reliable identification.

### Statistical analysis for comparative proteomics

The label-free quantification algorithm in Maxquant multilevel feedback queue (MLFQ) was used for semi-quantification between ofloxacin-treated and control groups.

Perseus software (<https://www.biochem.mpg.de/5111810/perseus>) was used for the statistical analysis. Principal component analysis (PCA) showed the overall effects of ofloxacin on *E. coli*. A two-sample t-test ( $p < 0.05$ ) was performed with 250 randomizations and a FDR of 1%, to identify the differentially expressed proteins between the control and ofloxacin-treated groups.

### Gene list, protein-protein interaction, and pathway analysis


Panther, the gene list software (<http://pantherdb.org>), was used to classify differentially expressed proteins according to cellular component, molecular function, and biological process. We also investigated the relationships of downregulated and upregulated proteins in a protein map by using the String functional tool (<https://string-db.org>). In addition, differentially expressed proteins were evaluated in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (<https://www.genome.jp/kegg/mapper.html>) to observe the ofloxacin-induced metabolic pathways.

## RESULTS

### LC/QTOF/MS proteomics assay

The determined MIC value for *E. coli* ATCC 25922 was 0.02 mg/L, which was in accordance with the EUCAST breakpoints. Thus, the 0.5x MIC value of 0.01 mg/L was used for proteomics experiments. The growth curve of *E. coli* ATCC 25922 after treatment with 0.01 mg/L of ofloxacin was constructed over 48 hours. The colony counts for treated bacterial cells were significantly different from those of the control at 6, 20, and 48 hours (Figure 1).

Proteins were extracted and digested from the control and ofloxacin-treated groups and analyzed in four technical



**Figure 1.** Growth curve of *Escherichia coli* ATCC 25922 with or without 0.02 mg/L ofloxacin treatment (0.5x MIC). Sampling for proteomic experiments was conducted at the 20<sup>th</sup> hour. Two-Way ANOVA was performed for multiple comparisons

\*:  $p < 0.05$ , \*\*\*\*:  $p < 0.0001$ , MIC: Minimum inhibitory concentration

replicates by using the LC/QTOF/MS system. Chromatograms are shown in Figure 2. Proteins were identified with a conservative threshold (FDR  $\leq 0.01$  and matched peptide numbers  $\geq 2$ ). In total, 649 common proteins were identified in the control and ofloxacin-treated groups. In the present study, we used micro-LC-based proteomics analysis. Micro LC-based proteomics is less sensitive but more robust and reproducible than nano LC-based proteomics. Thus, we identified fewer proteins than we would have using nano LC based proteomics.


The label-free protein quantification algorithm of Maxquant MLFQ was used for semi-quantitative proteomics. The MLFQ intensities of proteins were evaluated statistically. First, treated and untreated groups were analyzed individually through a multi-scatter plot analysis to observe the reproducibility of technical replicates. The Pearson's correlation coefficients were between 0.885 and 0.968 for the untreated group. For the treated group, the correlation coefficients ranged from 0.871 to 0.946. These results indicated highly reproducible findings between technical replicates. PCA was used to observe the global effect of ofloxacin on the *E. coli* proteome. In addition, PCA analysis was used to observe the similarity between the technical replicates of ofloxacin-treated and control groups (Figure 3). PCA results showed that ofloxacin significantly impacts proteome structure in *E. coli* (PC1 50.8%, PC2 19.2%).

The MLFQ intensities of proteins were evaluated using the statistical software Perseus. The two-sample t-test showed alterations in the expression levels of 98 proteins. A total of 30 proteins showed increased and 68 proteins showed decreased expression (altered proteins and fold changes are given in the supplementary material).

### Gene ontology (GO) analysis of differentially expressed proteins

Differentially expressed proteins were classified into GO categories. Proteins were first classified according to their location inside cells. Differentially expressed proteins were mostly located in the cytosol (34.88%), plasma membrane (23.26%), and ribosome (23.26%). Moreover, some of them were categorized as integral membrane (9.30%), mitochondrial (4.65%), adenosine triphosphate (ATP) synthase complex (2.33%), and nucleus-related proteins (2.33%) (Figure 4A).


The proteins were also evaluated to understand the effect of ofloxacin stress on biological processes. Proteins were mostly



**Figure 2.** Chromatograms of control and ofloxacin-treated groups

involved in metabolic processes (47.4%), cellular processes (36.6%), biogenesis (7.3%), localization (6.1%), and biological regulation (2.1%) (Figure 4B). As expected, metabolic processes were mainly altered in *E. coli* under ofloxacin stress. Since primary metabolic processes are essential for cell viability, those processes were analyzed in detail (Figure 4C).

According to the molecular functions of proteins (Figure 4D), it was determined that differentially expressed proteins have catalytic (44.6%), binding (21.5%), structural molecular (18.5%),



**Figure 3.** PCA analysis of treated and untreated groups. The blue zone shows the technical replicates of untreated groups, and the red zone shows the technical replicates of the treated group

PCA: Principal component analysis

translation regulatory (3.1%), transporter (9.2%), antioxidant (1.5%), and receptor activities (1.5%).

#### Protein interaction analysis

The string protein interaction tool was used to observe interactions between differentially expressed proteins in a protein map. Up- and downregulated proteins were analyzed separately (Figure 5A, 5B).


#### KEGG pathway analysis

Next, we evaluated increasing and decreasing proteins together in the KEGG pathway (FDR <0.05). The ofloxacin-induced metabolic pathways are presented in Figure 6. KEGG pathway analysis showed that the ofloxacin treatment mainly affects cells' metabolic functions (especially energy metabolism) and ribosomes. Other affected ofloxacin pathways include the following: Biosynthesis of secondary metabolites, microbial metabolism in diverse environments, carbon metabolism, biosynthesis of amino acids, pyruvate metabolism, methane metabolism, and purine metabolism.

## DISCUSSION

In the present study, changes in the proteome structure of *E. coli* were evaluated in response to ofloxacin exposure. PCA analysis showed that ofloxacin has a widespread effect on *E. coli*. Ninety-eight proteins were found to be altered in the ofloxacin-treated group.

The differentially expressed proteins were classified functionally in GO analysis to understand the systematic effect of ofloxacin on *E. coli* at the protein level. First, we classified



**Figure 4.** (A) Classification of differentially expressed proteins according to cellular component; (B) functional classification of differentially expressed proteins in cellular component; (C) ofloxacin-induced primary metabolic processes (nucleobase-containing compound metabolic process); (D) functional classification of differentially expressed proteins according to their molecular functions

ATP: Adenosine triphosphate






LigA has been evaluated as a potential antimicrobial target, and LigA inhibitors have shown promising results.<sup>21,22</sup> We believe that combination therapies including ofloxacin and LigA inhibitors can be more effective for resistant strains of *E. coli*.

We also observed that ofloxacin affects the expression levels of various heterocyclic-compound-binding proteins. Tryptophanase, (TnaA), which is responsible for the production of indole, is an important factor in biofilm formation and antibiotic resistance.<sup>23</sup> Previous studies have shown that the decrease in TnaA levels interrupts inter-species biofilm signaling and subsequently decreases biofilm formation.<sup>24</sup> In our study, TnaA was decreased in the presence of subinhibitory concentrations of ofloxacin. This result suggests that ofloxacin treatment may be considered in the treatment of biofilm-forming infections.

ATP synthase subunit alpha is another heterocyclic-compound-binding protein. Previous studies showed that inhibition of ATP synthase proteins caused dysregulation of energy metabolism and suppressed bacterial growth. ATP synthase is a promising target of many antibiotics.<sup>25</sup> In our study, the presence of the ATP synthase subunit alpha decreased in the ofloxacin-treated groups.

In protein interaction analysis, We investigated interactions of altered proteins in biological pathways. When downregulated proteins were evaluated with String analysis, it was observed that the disruption of ribosomal metabolism was likely to be closely related to energy metabolism, which was also largely affected by the reduction in outer membrane proteins such as LamB and MipA. As discussed above, MipA and LamB are important regulators in membrane-based resistance processes. The exact the interactions between ribosomal proteins, energy metabolism, and membrane proteins have not yet been elucidated. It can be hypothesized that the reduction in MipA and LamB may also lead to reduced intake of the essential factors related to ribosomal and energy metabolism, in addition to reduced antibiotic intake. KEGG pathway analysis also confirmed that ofloxacin treatment mainly affects cells' metabolic functions (especially energy metabolism) and ribosomes.



**Figure 6.** Ofloxacin-induced pathways (FDR <0.05)  
FDR: False discovery rate

According to the String analysis of upregulated proteins, the ribosomal proteins RpmE and RpsS were related to pyruvate metabolism and (tricarboxylic acid) TCA cycle proteins (MaeB, SucC, AccB). Rosato et al.<sup>26</sup> showed that the TCA cycle is upregulated under antibiotic stress, and dysregulated production of TCA cycle-mediated reactive oxygen species had an effect on DNA integrity and subsequently triggered activation of the SOS response. Due to the SOS response, RecA is upregulated for DNA repair,<sup>27</sup> which may result in enhanced mutagenesis and the development of resistance to antibiotics as a defense mechanism. We demonstrated upregulation of TCA cycle proteins; however, we did not observe RecA in our study, which might have been due to the concentration and exposure time of ofloxacin.

## CONCLUSION

The present study, which was designed to evaluate the effect of ofloxacin on *E. coli* proteomics and to elucidate additional resistance mechanisms, showed that ofloxacin has systematic effects on ribosomal processes, energy pathways, and various antimicrobial targets. Moreover, we found that various mechanisms may play a role in ofloxacin resistance, which requires confirmation by further dose- and time-dependent studies.

*Conflicts of interest: No conflict of interest was declared by the authors. The authors alone are responsible for the content and writing of the paper.*

## REFERENCES

- Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. *J Infect Dev Ctries.* 2014;8:129-136.
- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P T.* 2015;40:277-283.
- Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. *Microbiol Spectr.* 2016;4.
- Cohen A, Bont L, Engelhard D, Moore E, Fernández D, Kreisberg-Greenblatt R, Oved K, Eden E, Hays JP. A multifaceted 'omics' approach for addressing the challenge of antimicrobial resistance. *Future Microbiol.* 2015;10:365-376.
- Vranakis I, Goniou I, Psaroulaki A, Sandalakis V, Tselentis Y, Gevaert K, Tsiotis G. Proteome studies of bacterial antibiotic resistance mechanisms. *J Proteomics.* 2014;97:88-99.
- Pérez-Llarena FJ, Bou G. Proteomics as a tool for studying bacterial virulence and antimicrobial resistance. *Front Microbiol.* 2016;7:410.
- Lima TB, Pinto MF, Ribeiro SM, de Lima LA, Viana JC, Gomes Júnior N, de Souza Cândido E, Dias SC, Franco OL. Bacterial resistance mechanism: what proteomics can elucidate. *FASEB J.* 2013;27:1291-1303.
- Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. *Surv Ophthalmol.* 2004;49(Suppl 2):S73-S78.
- Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. *Clin Infect Dis.* 2001;32(Suppl 1):S9-S15.

10. Liu X, Zhang H, Li L, Fu C, Tu C, Huang Y, Wu L, Tang J, Luo Y, Christie P. Levels, distributions and sources of veterinary antibiotics in the sediments of the Bohai Sea in China and surrounding estuaries. *Mar Pollut Bull.* 2016;109:597-602.
11. Zhao S, Liu X, Cheng D, Liu G, Liang B, Cui B, Bai J. Temporal-spatial variation and partitioning prediction of antibiotics in surface water and sediments from the intertidal zones of the Yellow River Delta, China. *Sci Total Environ.* 2016;569-570:1350-1358.
12. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 10<sup>th</sup> ed. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
13. EUCAST. Recommendations for MIC determination of colistin ( polymyxin E ) As recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. 2016. Available from: [http://www.bioconnections.co.uk/files/merlin/Recommendations\\_for\\_MIC\\_determination\\_of\\_colistin\\_March\\_2016.pdf](http://www.bioconnections.co.uk/files/merlin/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf)
14. Lin XM, Yang JN, Peng XX, Li H. A novel negative regulation mechanism of bacterial outer membrane proteins in response to antibiotic resistance. *J Proteome Res.* 2010;9:5952-5959.
15. Li H, Zhang DF, Lin XM, Peng XX. Outer membrane proteomics of kanamycin-resistant *Escherichia coli* identified MipA as a novel antibiotic resistance-related protein. *FEMS Microbiol Lett.* 2015;362:fnv074.
16. Jones AK, Woods AL, Takeoka KT, Shen X, Wei JR, Caughlan RE, Dean CR. Determinants of antibacterial spectrum and resistance potential of the elongation factor g inhibitor argyrisin b in key gram-negative pathogens. *Antimicrob Agents Chemother.* 2017;61:e02400-e02406.
17. Koch A, Mizrahi V, Warner DF. The impact of drug resistance on *Mycobacterium tuberculosis* physiology: what can we learn from rifampicin? *Emerg Microbes Infect.* 2014;3:e17.
18. Karas VO, Westerlaken I, Meyer AS. The DNA-Binding Protein from Starved Cells (Dps) Utilizes Dual Functions To Defend Cells against Multiple Stresses. *J Bacteriol.* 2015;197:3206-3215.
19. Piras C, Soggiu A, Greco V, Martino PA, Del Chierico F, Putignani L, Urbani A, Nally JE, Bonizzi L, Roncada P. Mechanisms of antibiotic resistance to enrofloxacin in uropathogenic *Escherichia coli* in dog. *J Proteomics.* 2015;127:365-376.
20. Pesek J, Büchler R, Albrecht R, Boland W, Zeth K. Structure and mechanism of iron translocation by a Dps protein from *Microbacterium arborescens*. *J Biol Chem.* 2011;286:34872-34882.
21. Mills SD, Eakin AE, Buurman ET, Newman JV, Gao N, Huynh H, Johnson KD, Lahiri S, Shapiro AB, Walkup GK, Yang W, Stokes SS. Novel bacterial NAD<sup>+</sup>-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy *in vivo*. *Antimicrob Agents Chemother.* 2011;55:1088-1096.
22. Murphy-Benenato K, Wang H, McGuire HM, Davis HE, Gao N, Prince DB, Jahic H, Stokes SS, Boriack-Sjodin PA. Identification through structure-based methods of a bacterial NAD<sup>(+)</sup>-dependent DNA ligase inhibitor that avoids known resistance mutations. *Bioorg Med Chem Lett.* 2014;24:360-366.
23. Li G, Young KD. Indole production by the tryptophanase TnaA in *Escherichia coli* is determined by the amount of exogenous tryptophan. *Microbiology.* 2013;159:402-410.
24. Lee J JA, Wood TK, Jayaraman A. Indole is an inter-species biofilm signal mediated by SdiA. *BMC Microbiol.* 2007;7:42.
25. Ahmad Z, Okafor F, Azim S, Laughlin TF. ATP synthase: a molecular therapeutic drug target for antimicrobial and antitumor peptides. *Curr Med Chem.* 2013;20:1956-1973.
26. Rosato RR, Fernandez R, Paz LI, Singh CR, Rosato AE. TCA cycle-mediated generation of ROS is a key mediator for HeR-MRSA survival under beta-lactam antibiotic exposure. *PLoS One.* 2014;9:e99605.
27. Qin TT, Kang HQ, Ma P, Li PP, Huang LY, Gu B. SOS response and its regulation on the fluoroquinolone resistance. *Ann Transl Med.* 2015;3:358.